{"id":10390,"date":"2024-10-10T07:57:54","date_gmt":"2024-10-10T12:57:54","guid":{"rendered":"https:\/\/ibio.org\/?p=10390"},"modified":"2024-10-10T07:57:54","modified_gmt":"2024-10-10T12:57:54","slug":"breakthrough-in-parkinsons-treatment-vanqua-bios-vq-101-shows-promising-results","status":"publish","type":"post","link":"https:\/\/ibio.org\/breakthrough-in-parkinsons-treatment-vanqua-bios-vq-101-shows-promising-results\/","title":{"rendered":"Breakthrough in Parkinson’s Treatment: Vanqua Bio’s VQ-101 Shows Promising Results"},"content":{"rendered":"

Vanqua Bio has announced positive interim results from its Phase 1 clinical trial of VQ-101, a novel drug designed to treat GBA-Parkinson’s and related disorders. This breakthrough could potentially slow or even halt the progression of Parkinson’s disease, offering hope to millions of patients worldwide.<\/p>\n

Key Highlights:<\/h2>\n
    \n
  1. Impressive Enzyme Activation<\/strong>: VQ-101 demonstrated over 75% activation of the lysosomal enzyme glucocerebrosidase (GCase) in humans, exceeding the study’s target of 50%.<\/li>\n
  2. Safety and Tolerability<\/strong>: The drug was well-tolerated in healthy volunteers, with no serious adverse events reported.<\/li>\n
  3. Promising Brain Penetration<\/strong>: VQ-101 achieved significant levels in the cerebrospinal fluid, indicating full central nervous system penetrance.<\/li>\n
  4. Advancement to Patient Trials<\/strong>: Vanqua Bio has initiated the Phase 1b portion of the study in Parkinson’s patients, with results expected in 2025.<\/li>\n<\/ol>\n

    Why It Matters<\/h2>\n

    Parkinson’s disease affects millions of people globally, and current treatments only address symptoms without slowing disease progression. VQ-101’s ability to activate GCase and potentially stop the accumulation of alpha-synuclein (a hallmark of PD) could represent a game-changing approach to treatment.<\/p>\n

    Dr. Jim Sullivan, CEO of Vanqua Bio, expressed excitement about the results, stating, “These data reflect the considerable efforts of an experienced team that is passionate about making a difference in the lives of people living with PD.”<\/p>\n

    Looking Ahead<\/h2>\n

    As Vanqua Bio prepares for later-stage clinical studies, they’ve strengthened their team by appointing Dr. Maurizio Facheris as Chief Medical Officer. Dr. Facheris brings valuable experience in taking Parkinson’s therapies from early development to approval.<\/p>\n

    \n

    Note: This article has been written based on a press release<\/a> from Vanqua Bio dated October 09, 2024.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    Vanqua Bio has announced positive interim results from its Phase 1 clinical trial of VQ-101, a novel drug designed to treat GBA-Parkinson’s and related disorders. This breakthrough could potentially slow or even halt the progression of Parkinson’s disease, offering hope to millions of patients worldwide. Key Highlights: Impressive Enzyme Activation: VQ-101 demonstrated over 75% activation […]<\/p>\n","protected":false},"author":12,"featured_media":10392,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[145],"tags":[222,620],"class_list":["post-10390","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-community-news","tag-parkinsons","tag-vanqua"],"_links":{"self":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/comments?post=10390"}],"version-history":[{"count":1,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10390\/revisions"}],"predecessor-version":[{"id":10391,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10390\/revisions\/10391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media\/10392"}],"wp:attachment":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media?parent=10390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/categories?post=10390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/tags?post=10390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}